Prostate Cancer

  • In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that...

  • In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent — a...

  • An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. This androgen receptor pathway drives development and...

  • For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects. The findings come from research presented at the 58th annual meeting of the American Society for Radiation Oncology (ASTRO)...

  • The American Society for Radiation Oncology (ASTRO) announced the press program for its 58th Annual Meeting, Sept. 25-28 in Boston. The program includes multiple reports from phase III clinical trials, researchers from leading institutions in the United States and abroad, and examinations of a...

PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018

February 5, 2018 — Using nuclear...

New Data Examines Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients
News | Prostate Cancer | December 19, 2017

December 19, 2017 — Humanetics Corp. presented data at the annual meetings of the American Society for Radiation...

Synthetic CT Images Suitable for Prostate Cancer Radiotherapy Planning
News | Treatment Planning | November 14, 2017

November 14, 2017 — Spectronic Medical announced that new data for their MRIPlanner software, generating...

Proton Therapy Shows Promising Clinical Benefits for Esophageal, Prostate and Breast Cancer
News | Proton Therapy | October 30, 2017

October 30, 2017 — The National Association for Proton Therapy (NAPT) announced a number of clinical papers showing...

Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017

October 26, 2017 — The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer...

Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017

October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-...

CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017

October 10, 2017 — Accuray Inc. announced that data from a prospective study of 230 men with low-risk...

Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017

October 4, 2017 — Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an...

Immune Response Prognostic for Prostate Cancer Survival, Recurrence and Radiotherapy Response
News | Prostate Cancer | October 03, 2017

October 3, 2017 — A new study finds that immune response in...

Augmenix to Release New SpaceOAR Hydrogel Clinical Data at ASTRO 2017
News | Patient Positioning Radiation Therapy | September 22, 2017

September 22, 2017 — Augmenix Inc. announced a preview of...

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017

September 20, 2017 — ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free...

Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017

September 14, 2017 — Researchers have demonstrated a new, effective way to precisely identify and localize...

Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017

September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the...

U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017

September 8, 2017 — Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the...

Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017

September 5, 2017 — Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC)...

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017

August 16, 2017 — In the featured translational article in the August issue of ...

Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis
News | Biopsy Systems | July 17, 2017

July 17, 2017 — Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical...

Augmenix Announces First New Zealand Prostate Cancer Patient Treated with SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | June 28, 2017

June 28, 2017 — Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR...

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017

An estimated one in seven American men will be affected by...

Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017

In the battle against metastatic ...

Overlay Init